Patents by Inventor Sean G. Chadwick

Sean G. Chadwick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for determining azole resistance in
    Patent number: 8021846
    Abstract: There is disclosed a method for determining azole resistance in Candida glabrata. A biological sample containing Candida glabrata is obtained and a normalized mRNA level of CDR1 gene is determined using qRT-PCR. Using a microbroth dilution assay conducted at azole concentrations of about 2-8 ?g/mL, a susceptible isolate of Candida glabrata is obtained. A qRT-PCR assay is employed on the susceptible isolate and an average mRNA level of CDR1 is obtained. A fold-change value for CDR1 is obtained by comparing the CDR1 mRNA level of the biological sample with that of the average mRNA level. A ?2-fold change value is indicative of an azole resistance in Candida glabrata. The present method provides a qRT-PCR assay for azole resistance that has a sensitivity of ?90% and a specificity of ?90%.
    Type: Grant
    Filed: March 12, 2009
    Date of Patent: September 20, 2011
    Assignee: Medical Diagnostic Laboratories, LLC
    Inventors: Scott E. Gygax, John-Paul Vermitsky, Sean G. Chadwick, Matthew J. Self, Eli Mordechai, Martin E. Adelson
  • Method for determining azole resistance in candida glabrata
    Publication number: 20090305274
    Abstract: There is disclosed a method for determining azole resistance in Candida glabrata. A biological sample containing Candida glabrata is obtained and a normalized mRNA level of CDR1 gene is determined using qRT-PCR. Using a microbroth dilution assay conducted at azole concentrations of about 2-8 ?g/mL, a susceptible isolate of Candida glabrata is obtained. A qRT-PCR assay is employed on the susceptible isolate and an average mRNA level of CDR1 is obtained. A fold-change value for CDR1 is obtained by comparing the CDR1 mRNA level of the biological sample with that of the average mRNA level. A ?2-fold change value is indicative of an azole resistance in Candida glabrata. The present method provides a qRT-PCR assay for azole resistance that has a sensitivity of ?90% and a specificity of ?90%.
    Type: Application
    Filed: March 12, 2009
    Publication date: December 10, 2009
    Applicant: Medical Diagnostic Laboratories, LLC
    Inventors: Scott E. Gygax, John-Paul Vermitsky, Sean G. Chadwick, Matthew J. Self, Eli Mordechai, Martin E. Adelson